A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma

Official Title

A Phase 2 Open-Label, Multicentre Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women With Recurrent or Persistent Uterine Serous Carcinoma

Summary:

This is a Phase 2 study to evaluate the clinical activity, safety, pharmacokinetics (PK), and related biomarkers of ZN-c3 in adult women with recurrent or persistent uterine serous carcinoma (USC).

Trial Description

Primary Outcome:

  • To investigate the antitumour activity of ZN-c3 based on the objective response rate (ORR).
Secondary Outcome:
  • To investigate the antitumour clinical activity based on Duration of Response (DOR)
  • To investigate the antitumour clinical activity based on Progression-Free Survival (PFS)
  • To investigate the safety and tolerability of ZN-c3
This is a Phase 2 open-label, multicentre study to evaluate the clinical activity, safety, pharmacokinetics (PK), and related biomarkers of ZN-c3 in adult women with recurrent or persistent uterine serous carcinoma (USC).

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society